|
Author
|
Country (City)
|
Study design
|
Study period
|
Survived
|
Died
|
|---|
|
Age (years)
|
BMI (kg/m2)
|
Dyslipidemia (n)
|
Non-dyslipidemia (n)
|
Age (years)
|
BMI (kg/m2)
|
Dyslipidemia (n)
|
Non-dyslipidemia (n)
|
|---|
|
Almazeedi[13]
|
Kuwait
|
Cohort
|
Feb24–Apr20, 2020
|
38.7 ± 15.1
|
26.8 ± 5.9
|
62
|
1015
|
55.0 ± 10.1
|
33 ± 4.7
|
3
|
16
|
|
Khalil[27]
|
UK(London)
|
Cohort
|
Mar7–Apr7, 2020
|
63.8 (61.1–66.4)
|
NA
|
34
|
128
|
75.8 (72.5–79.2)
|
NA
|
16
|
42
|
|
Gayam[28]
|
USA(New York)
|
Cohort
|
Mar1–Apr9, 2020
|
63 [53–73]
|
28.3 [25.0–33.6]
|
41
|
235
|
71 [62–80]
|
31.8 [26.5–37]
|
25
|
107
|
|
Goicoechea[29]
|
Spain
|
Cohort
|
Mar12–Apr10, 2020
|
69 ± 14
|
27.2 ± 4.5
|
18
|
7
|
75 ± 6
|
25.1 ± 3.6
|
6
|
5
|
|
Santos[30]
|
Spain (Leon)
|
Cohort
|
Mar1–Jun1, 2020
|
75.1 [69.3–75.8]
|
NA
|
12
|
16
|
78.4 [74.5–83.5]
|
NA
|
9
|
1
|
|
Wang[31]
|
USA (New York)
|
Cohort
|
Mar1–Apr30, 2020
|
71 [18.5]
|
28.2 [10.2]
|
13
|
9
|
68 [8]
|
29.5 [9.9]
|
12
|
2
|
|
Ferrando[32]
|
Spain
|
Cohort
|
Mar12–May16, 2020
|
62 [53–71]
|
28.6 [25.7–32.4]
|
55
|
405
|
68 [62–73]
|
27.7 [25.3–31.6]
|
35
|
168
|
|
Zhang[19]
|
China (Beijing)
|
Cohort
|
Jan–Feb, 2020
|
NA
|
NA
|
2
|
75
|
84.00 ± 8.185
|
NA
|
1
|
2
|
|
Hwang[33]
|
South Korea (Daegu)
|
Cohort
|
Feb1–Mar25, 2020
|
64.62 ± 15.84
|
NA
|
10
|
67
|
76.50 ± 9.25
|
NA
|
3
|
23
|
|
Smith[34]
|
New England
|
Cohort
|
Mar1–Apr22, 2020
|
63.56
|
30.94
|
107
|
122
|
73.31
|
29.85
|
60
|
57
|
|
Grasselli[35]
|
Italy (Milan)
|
Cohort
|
Feb20–Apr22, 2020
|
NA
|
NA
|
169
|
1893
|
NA
|
NA
|
376
|
1550
|
- Data are expressed as mean ± standard deviation; median [interquartile range]; mean (95%Confidence interval)
- COVID-19 coronavirus disease, NA not available, n number, BMI body mass index
